Overview A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) Status: Not yet recruiting Trial end date: 2027-03-01 Target enrollment: Participant gender: Summary This study will evaluate the safety and efficacy of MIL62 in patients with Neuromyelitis Optica Spectrum Disorder. Phase: Phase 3 Details Lead Sponsor: Beijing Mabworks Biotech Co., Ltd.